Latest News from: Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Filters close

Not for public release

This news release is embargoed until 16-Sep-2024 11:00 AM EDT Released to reporters: 13-Sep-2024 3:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 16-Sep-2024 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
Newswise: Making Connections will be the focus at the ACTRIMS Forum 2025
Released: 1-Aug-2024 12:05 PM EDT
Making Connections will be the focus at the ACTRIMS Forum 2025
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is excited to announce its tenth annual Forum, taking place from February 27 to March 1, 2025, at the Palm Beach County Convention Center and the Hilton West Palm Beach in Florida.

Comment
   
Newswise: National MS Society Awards Dr. Sergio Baranzini the Barancik Prize for Innovation in MS Research
Released: 30-Jan-2024 11:05 AM EST
National MS Society Awards Dr. Sergio Baranzini the Barancik Prize for Innovation in MS Research
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Sergio E. Baranzini, PhD, a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco, is the winner of this year’s Barancik Prize for Innovation in MS Research.

Comment
Newswise: The ninth annual ACTRIMS Forum will be held Feb. 29 - March 2 in West Palm Beach, Florida.
Released: 3-Aug-2023 11:30 AM EDT
The ninth annual ACTRIMS Forum will be held Feb. 29 - March 2 in West Palm Beach, Florida.
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Breaking Barriers in MS will be the focus at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024

Comment
19-Jul-2023 2:30 PM EDT
Is it MS or Something Else? Updated Guide is Published to Expedite and Uncover the Answer
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

An international consortium led by ACTRIMS has published detailed updated recommendations for how to distinguish suspected multiple sclerosis from other look-alike disorders. This critical guidance aims to reduce the time spent to confirm an accurate diagnosis of MS.

Comment
Newswise: ACTRIMS Forum 2023 themed MS: Going Viral
Released: 8-Sep-2022 1:05 PM EDT
ACTRIMS Forum 2023 themed MS: Going Viral
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual Forum will be held Feb. 23-25, 2023, in San Diego, California at the Marriott Marquis San Diego Marina. Themed “MS: Going Viral,” the Forum 2023, will address the role of different viruses that have been implicated in the ongoing disease process in MS, in particular the Epstein-Barr virus, which has been associated with the onset of MS. The Forum also features the Kenneth P. Johnson Memorial Lecture, which will be delivered by Dr. Lawrence Steinman.

Comment
Newswise: ACTRIMS Board Member Dr. Amit Bar-Or Wins Barancik Prize for Innovation in MS Research
Released: 17-Feb-2022 4:05 PM EST
ACTRIMS Board Member Dr. Amit Bar-Or Wins Barancik Prize for Innovation in MS Research
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

The National MS Society announced that Amit Bar-Or, MD, the Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania is this year’s recipient of the Barancik Prize for Innovation in MS Research. He is being honored for work uncovering how the immune system drives MS and for cutting-edge research focusing on precision medicine to achieve long-term remission and ultimately preventing progression of the disease.

Comment
Released: 22-Feb-2021 1:05 PM EST
Evolution of the Neuroinflammatory Response Over the Clinical Course of MS
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Benjamin M. Segal, M.D., The Ohio State University, to present keynote address at ACTRIMS Forum 2021

Comment
Released: 19-Jan-2021 11:40 AM EST
The Spectrum of Multiple Sclerosis will be the focus at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Forum Announcement

Comment
16-Sep-2020 5:10 PM EDT
Q&A with Leaders of MS Virtual 2020 Conference
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

ACTRIMS MS Virtual 2020 Q&A with Association Leadership

Comment
22-Sep-2020 9:50 AM EDT
Primary astrocytopathy has a detrimental effect on remyelination efficacy of parenchymal oligodendrocyte precursor cells
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comment
22-Sep-2020 12:45 PM EDT
First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are associated with worse COVID-19 outcomes
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comment
22-Sep-2020 12:10 PM EDT
Evidence of an Increased Burden of Humoral Autoimmunity in the CSF and plasma of COVID-19 Patients with Comorbid Neurologic Dysfunction
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Coronavirus disease 19 (COVID-19) is the most globally impactful pandemic of the past century.

Comment
22-Sep-2020 12:05 PM EDT
Comparison of COVID-19 outcomes between racial groups in the COViMS registry
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comment
22-Sep-2020 11:05 AM EDT
Network analysis identifies gut bacteria associated with multiple sclerosis relapse among pediatric-onset patients
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comment
22-Sep-2020 10:15 AM EDT
Neutrophil granulocyte markers in cerebrospinal fluid differentiate NMOSD and anti-MOG antibody associated disease from MS in acute disease phase
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comment
22-Sep-2020 10:05 AM EDT
Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comment
22-Sep-2020 11:40 AM EDT
COVID-19 in people with MS: A large community-based study of the UK MS Register
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comment
22-Sep-2020 11:15 AM EDT
Interrupting disease modifying treatment for pregnancy in multiple sclerosis – effect on disease activity and serum neurofilament light chain
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comment
22-Sep-2020 10:30 AM EDT
Brain microstructural and metabolic alterations detected in vivo at the onset of the first demyelinating event
 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comment


close
2.1365